Stock listing

ABCL Stock Price, News, Filings & Events — Abcellera Biologics Inc.

Selected listing: ABCL · BX · CHF · CH

This page tracks Abcellera Biologics Inc.'s ABCL:BX listing on BX in CHF for CH, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following ABCL:BX. ABCL:BX is the stock-level entry point for investors researching Abcellera Biologics Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Abcellera Biologics Inc. is a public company traded under the ticker ABCL in the American market. The company has a market capitalization of approximately $1.97 billion. Abcellera focuses on advancing its proprietary technology for antibody discovery and development.

ABCL:BXCHFCHUpdated August 21, 2026
Abcellera Biologics Inc. logo
Ticker
ABCL:BX
Asset type
Stock
Market cap
$3.67B
Sector
Health Technology
Industry
Biotechnology
Exchange
BX
Currency
CHF

Abcellera Biologics Inc. ABCL:BX stock context

This page tracks Abcellera Biologics Inc.'s ABCL:BX listing on BX in CHF for CH, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following ABCL:BX. ABCL:BX is the stock-level entry point for investors researching Abcellera Biologics Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Abcellera Biologics Inc. is a public company traded under the ticker ABCL in the American market. The company has a market capitalization of approximately $1.97 billion. Abcellera focuses on advancing its proprietary technology for antibody discovery and development.

Latest news from Abcellera Biologics Inc.

All Abcellera Biologics Inc. news →

Research Abcellera Biologics Inc.

Alternate listings